Corvus Pharmaceuticals Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $8.33 on 10/22/24, while the lowest price for the same period was registered at $1.05 on 10/30/23.
52-week price history of CRVS Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Corvus Pharmaceuticals Inc’s current trading price is -5.16% away from its 52-week high, while its distance from the 52-week low is 652.38%. The stock’s price range during this period has spanned from $1.05 to $8.33. In the Healthcare sector, the Corvus Pharmaceuticals Inc’s shares surpassed a trading volume of approximately 0.8 million for the day, which was noticeably higher compared to the average daily volume of 9.0.51 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Corvus Pharmaceuticals Inc (CRVS) has experienced a quarterly rise of 206.20% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 494.15M and boasts a workforce of 28 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.82, with a change in price of +5.77. Similarly, Corvus Pharmaceuticals Inc recorded 386,746 in trading volume during the last 100 days, posting a change of +261.09%.
Examining CRVS’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CRVS stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
CRVS Stock Stochastic Average
Today, Corvus Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 92.75%, indicating a rise from the raw stochastic average of the last 20 days, which was 90.08%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 83.95% and 85.67% respectively.
CRVS Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price increase of 348.86%. However, over the past six months, we’ve seen a weaker performance of 433.78%. The price of CRVS fallen by 51.92% over the last 30 days. And in the last five days, it has surged by 9.57%.
